On the stock market since 2013, it operates in the world of health and science. It has 462 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 15% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $63.9M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 26% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 12% a year on average.
There is $75.5M in the vault; even if every debt were paid off, $63.9M would remain.
The average analyst price target is $13.00 — 88% above today’s price.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, KMDA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: KMDA is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.